GlassScriptPhysician profile
Jurate S Brigham
NPI 1477306033
$3,142.05
in general payments reported to CMS, 2019-2025
19 companies · $2,550 in 2025
The $2,550 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $592 · 2025: $2,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.56 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $536.74 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $496.41 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $483.37 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $471.70 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $281.49 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $174.40 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $149.87 | 2024-2025 | Sunosi, Auvelity |
| Lundbeck LLC | $125.30 | 2024-2025 | Rexulti, Vyepti |
| Biogen, INC. | $80.08 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $79.32 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $43.77 | 2024-2025 | Ingrezza |
| Vertex Pharmaceuticals Incorporated | $42.18 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.09 | 2025 | Rejoyn |
| Neos Therapeutics, LP | $24.84 | 2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $24.18 | 2024 | Belbuca |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $24.17 | 2025 | Movantik |
| Livanova USA, INC. | $23.59 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.56 | 2025 | Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $18.99 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jurate Brigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.